“ Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally. ”

Dan Harma, Chief Commercial Officer at Pillar Biosciences